Innate Pharma moves on from a trial disaster with a €40M in-licensing pact with Novo Nordisk
Just four months after its lead therapy lirilumab flunked a mid-stage test fighting acute myeloid leukemia, France’s Innate Pharma has exchanged a chunk of equity for a new immuno-oncology drug candidate from Novo Nordisk.
The drug — which Novo has tested in a pair of Phase I rheumatoid arthritis studies — is an anti-C5aR antibody aimed at the “accumulation and activation of myeloid-derived suppressor cells (MDSC) and neutrophils in the tumor microenvironment.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.